Industry-leading ADHD test is the first and only digital technology to assess ADHD and achieve approval
LONDON – (Business Wire) – The National Institute for Clinical Excellence (NICE), a UK government-funded non-dyadic staff body aiming to establish guidelines for clinical best practice, has published QBTECH’s objective ADHD assessment. Testing techniques were formally evaluated and recommended. QBTEST, within the National Health and Care Excellence Diagnostic Assessment Programme. This milestone positions QBTEST as the first and only digital technology recommended by NICE for ADHD diagnostic support and represents a significant breakthrough in the way ADHD is assessed in the National Health Service (NHS) and beyond. I am.
QBTEST is an FDA-cleared, market-leading computer-based test with motion tracking that objectively measures core ADHD symptoms: inattention, impulsivity, and hyperactivity. Results are analyzed and presented in an easy-to-read visual report comparing to a normative control group of the same age and gender who do not have ADHD. By integrating QBTEST with standard clinical assessments, clinicians can make faster and more accurate diagnostic decisions. Ultimately improving patient outcomes and reducing NHS waiting times.
“From a clinical perspective, QBTEST has allowed clinical services to arrive at a diagnosis of ADHD or other explanations of the condition. These services are in large demand from the NHS, so this technology has “We need more than just that,” says Professor Richard Morris (NIHR, 2024), NIHR ARC East Midlands Theme Lead for Mental Health and Wellbeing and Professor of Psychiatry at the University of Nottingham.
QBTEST’s inclusion in the Nice Diagnostic Guidelines (DG60) highlights its effectiveness in streamlining the ADHD diagnostic process in a variety of clinical settings. As part of a national program (Focus ADHD) funded by NHS England, QBTEST has been integrated into 15 Health Innovation Networks (HINs) across England, delivering 95,097 hours of healthcare capacity and delivering 1,582 clinical appointments across the NHS. I saved. (Nihr, 2024) (Network, 2024)
A landmark RCT study (Hollis, 2018) showed that when QBTEST was used alongside standard clinical assessments, diagnostic decisions were made significantly faster without compromising accuracy. Key findings:
A shorter appointment was required to reach a diagnostic decision. Clinicians were twice as likely to rule out ADHD much earlier in the assessment. Up to 44% more patients made a diagnostic decision within the first 6 months of evaluation compared to standard evaluation alone.
These findings are also supported by five additional studies in which QBTECH technology has been shown to reduce the number of consultations needed to reach a diagnosis (Nice Digital Technology for Diagnostic Assessment of ADHD , 2024).
QBTECH’s objective ADHD testing technology is used by more than 12,000 clinicians in 44 states in the United States and is routinely used at a national level by organizations such as the NHS in the United Kingdom. This technology has been documented in over 40 independent studies and has been shown to improve access to care, increase clinician confidence, better identify treatment effects than self-assessment, and standardize care in multiple areas. , demonstrating benefits across the patient care pathway.
About qbtech
Founded in 2002, QBTECH is a privately owned Swedish company that has developed leading solutions and products to improve the identification, diagnosis, treatment and follow-up of patients with ADHD. QBTECH operates in 15 countries and has offices in Stockholm, Houston and London. QBTECH is an award-winning company recognized for its innovation, recently winning the 2022 HSJ Partnership Award for ‘Best Mental Health Partnership with the NHS’. For more information about QBTECH, please visit www.qbtech.com.
contact address
Hilari Barton, Trevelino/Keller
qbtech@trevelinokeller.com
